

## SPECIAL FEATURES

## Highlights of This Issue 3197

## CCR Translations

**3199** The Dark Side of Innate Immunity Fosters Tumor Growth and Offers New Diagnostic

Ennio Carbone

*See related article, p. 3304***3202** One Clever Macrophage Checkpoint

Alberto Mantovani and Raffaella Bonecchi

*See related article, p. 3289*

## CCR Drug Updates

**3205** FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation

Kelly J. Norsworthy, Lola Luo, Vicky Hsu, Ramadevi Gudi, Sarah E. Dorff, Donna Przepiorka, Albert Deisseroth, Yuan-Li Shen, Christopher M. Sheth, Rosane Charlab, Gene M. Williams, Kirsten B. Goldberg, Ann T. Farrell, and Richard Pazdur

## Review

**3210** Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?

Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, Maria Ochoa de Olza, and Elena Garralda

## CLINICAL TRIALS: TARGETED THERAPY

**3220** Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D. Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F. Stephen Hodi, Myung-Ju Ahn, Leisha A. Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tshako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, and S. Lindsey Davis

**3229** A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Yael P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernan Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, and Brenda J. Weigel

## CLINICAL TRIALS: IMMUNOTHERAPY

**3239** Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF<sup>V600</sup>-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, and Antoni Ribas

## PRECISION MEDICINE AND IMAGING

**3247** Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

Jarem Edwards, Annie Tasker, Inês Pires da Silva, Camelia Quek, Marcel Batten, Angela Ferguson, Ruth Allen, Benjamin Allanson, Robyn P.M. Saw, John F. Thompson, Alexander M. Menzies, Umaimainthan Palendira, James S. Wilmott, Georgina V. Long, and Richard A. Scolyer

**3259** Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

Andrew B. Lassman, Lisa Roberts-Rapp, Irina Sokolova, Minghao Song, Ekaterina Pestova, Rupinder Kular, Carolyn Mullen, Zheng Zha, Xin Lu, Erica Gomez, Anahita Bhatena, David Maag, Priya Kumthekar, Hui K. Gan, Andrew M. Scott, Maria Guseva, Kyle D. Holen, Peter J. Ansell, and Martin J. van den Bent






**3266** Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging

Yiwen Xu, Ahmed Hosny, Roman Zeleznik, Chintan Parmar, Thibaud Coroller, Idalid Franco, Raymond H. Mak, and Hugo J.W.L. Aerts

# Table of Contents

- 3276** Targeted Assessment of *G0S2* Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma  
Dipika R. Mohan, Antonio Marcondes Lerario, Tobias Else, Bhramar Mukherjee, Madson Q. Almeida, Michelle Vinco, Juilee Rege, Beatriz M. P. Mariani, Maria Claudia N. Zerbini, Berenice B. Mendonca, Ana Claudia Latronico, Suely K. N. Marie, William E. Rainey, Thomas J. Giordano, Maria Candida B. V. Fragoso, and Gary D. Hammer

## TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 3289** Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8<sup>+</sup> T-cell Response against Immunosuppressive Tumors  
 Miro Viitala, Reetta Virtakoivu, Sina Tadayon, Jenna Rannikko, Sirpa Jalkanen, and Maija Hollmén  
*See related commentary, p. 3202*
- 3304** Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma  
Meng Duan, Shyamal Goswami, Jie-Yi Shi, Lin-Jie Wu, Xiao-Ying Wang, Jia-Qiang Ma, Zhao Zhang, Yang Shi, Li-Jie Ma, Shu Zhang, Rui-Bin Xi, Ya Cao, Jian Zhou, Jia Fan, Xiao-Ming Zhang, and Qiang Gao  
*See related commentary, p. 3199*
- 3317** A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis  
 Zhijun Zhou, Guanggai Xia, Zhen Xiang, Mingyang Liu, Zhewei Wei, Jie Yan, Wei Chen, Jintao Zhu, Niranjana Awasthi, Xiaotian Sun, Kar-Ming Fung, Yulong He, Min Li, and Changhua Zhang
- 3329** PDK1 Mediates *NOTCH1*-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition  
Vaishnavi Sambandam, Mitchell J. Frederick, Li Shen, Pan Tong, Xiayu Rao, Shaohua Peng, Ratnakar Singh, Tuhina Mazumdar, Chenfei Huang, Qiuli Li, Curtis R. Pickering, Jeffery N. Myers, Jing Wang, and Faye M. Johnson
- 3341** On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation  
 Benjamin P. Brown, Yun-Kai Zhang, David Westover, Yingjun Yan, Huan Qiao, Vincent Huang, Zhenfang Du, Jarrod A. Smith, Jeffrey S. Ross, Vincent A. Miller, Siraj Ali, Lyudmila Bazhenova, Alexa B. Schrock, Jens Meiler, and Christine M. Lovly
- 3352** Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination  
Shelby Lennon, Ayman Oweida, Dallin Milner, Andy V. Phan, Shilpa Bhatia, Benjamin Van Court, Laurel Darragh, Adam C. Mueller, David Raben, Jorge L. Martínez-Torrecuadrada, Todd M. Pitts, Hilary Somerset, Kimberly R. Jordan, Kirk C. Hansen, Jason Williams, Wells A. Messersmith, Richard D. Schulick, Philip Owens, Karyn A. Goodman, and Sana D. Karam
- 3366** Tissue 2-Hydroxyglutarate as a Biomarker for *Isocitrate Dehydrogenase* Mutations in Gliomas  
Hao-Wen Sim, Romina Nejad, Wenjiang Zhang, Farshad Nassiri, Warren Mason, Kenneth D. Aldape, Gelareh Zadeh, and Eric X. Chen
- 3374** The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in *PIK3CA*-Mutant Breast Cancer Brain Metastases  
Franziska M. Ippen, Christopher A. Alvarez-Breckenridge, Benjamin M. Kuter, Alexandria L. Fink, Ivanna V. Bihun, Matthew Lastrapes, Tristan Penson, Stephen P. Schmidt, Gregory R. Wojtkiewicz, Jianfang Ning, Megha Subramanian, Anita Giobbie-Hurder, Maria Martinez-Lage, Scott L. Carter, Daniel P. Cahill, Hiroaki Wakimoto, and Priscilla K. Brastianos
- 3384** Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa–Associated Squamous Cell Carcinoma  
Velina S. Atanasova, Celine Pourreyron, Mehdi Farshchian, Michael Lawler, Christian A. Brown IV, Stephen A. Watt, Sheila Wright, Michael Warkala, Christina Guttmann-Gruber, Josefina Piñón Hofbauer, Ignacia Fuentes, Marco Prisco, Elham Rashidghamat, Cristina Has, Julio C. Salas-Alanis, Francis Palisson, Alain Hovnanian, John A. McGrath, Jemima E. Mellerio, Johann W. Bauer, and Andrew P. South
- 3392** ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment  
 Magnus T. Dillon, Katharina F. Bergerhoff, Malin Pedersen, Harriet Whittock, Eva Crespo-Rodriguez, Emmanuel C. Patin, Alex Pearson, Henry G. Smith, James T.E. Paget, Radhika R. Patel, Shane Foo, Galabina Bozhanova, Chanthirika Ragulan, Elisa Fontana, Krisha Desai, Anna C. Wilkins, Anguraj Sadanandam, Alan Melcher, Martin McLaughlin, and Kevin J. Harrington
- 3404** Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors  
 Jonathan M. Cooper, Amish J. Patel, Zhiguo Chen, Chung-Ping Liao, Kun Chen, Juan Mo, Yong Wang, and Lu Q. Le

# Table of Contents

**3417** **Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner**



Matt L. Harlow, Maggie H. Chasse, Elissa A. Boguslawski, Katie M. Sorensen, Jenna M. Gedminas, Susan M. Kitchen-Goosen, Scott B. Rothbart, Cenny Taslim, Stephen L. Lessnick, Anderson S. Peck, Zachary B. Madaj, Megan J. Bowman, and Patrick J. Grohar

**3430** **Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck**

Jong Woo Lee, Janaki Parameswaran, Teresa Sandoval-Schaefer, Kyung Jin Eoh, Dong-hua Yang, Fang Zhu, Raneer Mehra, Roshan Sharma, Stephen G. Gaffney, Elizabeth B. Perry, Jeffrey P. Townsend, Ilya G. Serebriiskii, Erica A. Golemis, Natalia Issaeva, Wendell G. Yarbrough, Ja Seok Koo, and Barbara Burness

**3443** **PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma**



Henry G. Smith, David Mansfield, Victoria Roulstone, Joan N. Kyula-Currie, Martin McLaughlin, Radhika R. Patel, Katharina F. Bergerhoff, James T. Paget, Magnus T. Dillon, Aadil Khan, Alan Melcher, Khin Thway, Kevin J. Harrington, and Andrew J. Hayes

**3455** **B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density**

Phyu P. Aung, Edwin Roger Parra, Souptik Barua, Dawen Sui, Jing Ning, Barbara Mino, Debora Alejandra Ledesma, Jonathan L. Curry, Priyadharsini Nagarajan, Carlos A. Torres-Cabala, Eleni Efstathiou, Anh G. Hoang, Michael K. Wong, Jennifer A. Wargo, Alexander J. Lazar, Arvind Rao, Victor G. Prieto, Ignacio Wistuba, and Michael T. Tetzlaff

## LETTERS TO THE EDITOR

**3468** **Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers—Letter**

Roberto Ferrara, Sandrine Susini, and Aurelien Marabelle

**3469** **Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers—Response**


Anu Sharma, Sumit K. Subudhi, Jorge Blando, Luis Vence, Jennifer Wargo, James P. Allison, Antoni Ribas, and Padmanee Sharma

 AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows a histological section of a patient-derived xenograft from a pancreatic cancer patient implanted into mice. Stromal fibrosis was assessed by PicroSirius staining and imaging through polarized light. For details, see the article by Lennon and colleagues on page 3352 of this issue.



# Clinical Cancer Research

**25 (11)**

*Clin Cancer Res* 2019;25:3197-3470.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/25/11>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/25/11>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.